Read More

Candel Therapeutics Announces Late-breaking Oral Presentation At SITC Annual Meeting With Data On CAN-2409 In Combination With Nivolumab In A Phase 1 Mechanistic Clinical Trial In Patients With High-grade Glioma

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standard of care Systemic immune activation was observed in peripheral

CADL

Read More

Tesla, AT&T, AMD, Nvidia, Candel Therapeutics: Why These 5 Stocks Are Seeing High Attention Today

Major U.S. indices closed in the red on Thursday as investors continued to digest higher Treasury yields as well as key earnings. The yield in the benchmark U.S. 10-year Treasuries topped 4.239%, a level unseen since 2008. Benzinga dives into five stocks that are seeing high interest among retail investors today, as the U.S.

AMD